| EVOLUS INC. DL-,00001 |
| USA |
| Gesundheit |
| US30052C1071 / A2JDYX |
| EVL (Frankfurt) / EOLS (NASDAQ) |
| FRA:EVL, ETR:EVL, EVL:GR, NASDAQ:EOLS |
| - |
| https://www.evolus.com/ |
|
Evolus Inc. is a medical aesthetics company that is primarily known for its focus on aesthetic dermatology. The company's flagship product is Jeuveau, a botulinum toxin type A formulation intended for..
>Volltext.. |
| 239.83 Mio. EUR |
| 335.5 Mio. EUR |
| 246.51 Mio. EUR |
| -28.67 Mio. EUR |
| -50.51 Mio. EUR |
| -0.79 EUR |
| 133.59 Mio. EUR |
| 37.54 Mio. EUR |
| -43.37 Mio. EUR |
| 0.65 |
| 9.21% |
| -0.19% |
| - |
| - |
| - |
| - |
| EVOLUS |
| 04.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|